Pharma merger study shows cost savings don't always reach consumers

An analysis of the 2019 GSK-Pfizer consumer health merger in the Philippines found that while the combined business became cheaper to operate, those savings were not passed on as lower prices. Instead, a major rival's prices rose substantially. The study, published in the Southern Economic Journal, suggests merger efficiencies may not offset competitive harm.